Singapore: China based Hangzhou Tigermed Consulting has acquired a majority of Frontage Laboratories, a company providing bioanalysis, preclinical studies, early phase clinical studies and product development services for biopharmaceutical organizations.

Tigermed is engaged in outsourcing clinical development services across China and Asia Pacific regions to the pharmaceutical and medical device industries has acquired a majority position in the ownership of Frontage, a recognized leader in bioanalysis, preclinical studies, early phase clinical studies and product development services for biopharmaceutical organizations.

"Our strategic partnership with Frontage firmly establishes our global clinical trial network," said Dr Xiaoping Ye, founder and CEO, Tigermed. "The two companies share similar philosophies and operational approaches, which combined with additional complementary strengths in research integrity and reliability will now benefit clients on a much larger scale."

"Joining efforts with Tigermed allows us to expand our geographic range and align our early development services with Tigermed's late phase clinical operations for a scope that will serve clients looking for full-service, high quality, global drug development resources," said Song Li, founder and CEO, Frontage.